Quoin Pharmaceuticals (QNRX) 6-K Cellect Biotechnology Receives Approval for U.S. Clinical Trial

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of December 2019 (No. 1)

Commission File Number 001-37846

CELLECT BIOTECHNOLOGY LTD.

(Translation of registrant’s name into English)

23 Hata’as Street

Kfar Saba, Israel 44425

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F ☒    Form 40-F ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):                

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):                 

EXPLANATORY NOTE

On December 23, 2019, Cellect Biotechnology Ltd. issued a press release entitled “Cellect Biotechnology Receives Approval for U.S. Clinical Trial.” Attached hereto and incorporated by reference herein is the following exhibit: 

Exhibit

99.1 Press Release, dated December 23, 2019

-1-

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	CELLECT BIOTECHNOLOGY LTD.
Date: December 23, 2019	By:	/s/ Eyal Leibovitz
		Eyal Leibovitz
		Chief Financial Officer

-2-